Tumor-Educated Platelet miR-18a-3p as a Novel Liquid-Biopsy Biomarker for Early Diagnosis and Chemotherapy Efficacy Monitoring in Nasopharyngeal Carcinoma

• Published in: Frontiers in oncology Vol. 11; p. 736412
• Main Authors: Sun, Kaiyu, Wang, Hui, Xu, Xianqun, Wei, Xiuqi, Su, Jingyu, Zhu, Kaidong, Fan, Junli
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.10.2021
• Subjects: chemotherapy; early diagnosis; liquid-biopsy; miR-18a-3p; nasopharyngeal carcinoma; Oncology; tumor-educated platelet; early diagnosis; miR-18a-3p; liquid-biopsy; nasopharyngeal carcinoma; chemotherapy; tumor-educated platelet
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.736412

To evaluate the value of tumor-educated platelet (TEP) miR-18a-3p in the early diagnosis and chemotherapy efficacy monitoring of nasopharyngeal carcinoma (NPC). Expression levels of miR-18a-3p in platelets and plasma were detected by relative quantitative real-time PCR in NPC patients (n=54) and normal subjects (n=36). Diagnostic values of TEP miR-18a-3p for NPC was assessed by receiver operating characteristic (ROC) curve analysis. Follow up study was carried out to observe the dynamic changes of TEP miR-18a-3p with chemotherapy on 3 NPC patients. The expression levels of TEP miR-18a-3p in NPC patients were significantly higher than that in healthy controls ( < 0.0001). ROC curve analysis showed that the area under the curve (AUC) value was 0.841, the sensitivity and specificity for the diagnosis of NPC were 87% and 72.7%. No correlation was found between expression levels of TEP miR-18a-3p and patients' clinical parameters and their NPC tumor-node-metastasis (TNM) stage. The positive rate of TEP miR-18a-3p and EBV DNA for NPC diagnosis were 85.4% and 66.7%. TEP miR-18a-3p expression were down-regulated after 77.8% (7 of 9) of chemotherapy, and in 66.7% (2 of 3) patients, TEP miR-18a-3p levels decreased after 3 cycles of chemotherapy. The expression levels of TEP miR-18a-3p are upregulated in NPC and have a high probability to downregulated after chemotherapy, indicating a significant clinical value. TEP miR-18a-3p might serve as a novel type of liquid-biopsy biomarker for early diagnosis and chemotherapy efficacy monitoring in NPC.